(Total Views: 238)
Posted On: 03/03/2017 11:07:37 AM
Post# of 15624
Re: Makingbank #302
You won't recognize $OWCP in one year. I'm holding the majority of my stock for 2018 so I can reduce capital gains.
Anyway, in one year OWCP will:
Be selling psoriasis cream worldwide.
Likely be selling other creams worldwide.
Will be licensing its IP protected topical cream delivery system to other companies, from Canadian LPs who want to expand from flower and oils, to other pre-clinical companies that want a safety approved delivery tool for their own FDA trials.
Will be licensing its IP protected sublingual tablet to other companies, from Canadian LPs who realize there is a huge market for people who don't want to smoke, to other pre-clinical companies that want a way to deliver a precise and controlled amount of cannabinoids in their FDA trials.
More consulting agreements (OWCP currently has 3 consulting agreements).
Phase 1 FDA for sublingual tablet to treat PTSD.
Phase 1 FDA for sublingual tablet to treat Migraines.
Phase 1 FDA for sublingual tablet to treat multiple myeloma.
Anyway, in one year OWCP will:
Be selling psoriasis cream worldwide.
Likely be selling other creams worldwide.
Will be licensing its IP protected topical cream delivery system to other companies, from Canadian LPs who want to expand from flower and oils, to other pre-clinical companies that want a safety approved delivery tool for their own FDA trials.
Will be licensing its IP protected sublingual tablet to other companies, from Canadian LPs who realize there is a huge market for people who don't want to smoke, to other pre-clinical companies that want a way to deliver a precise and controlled amount of cannabinoids in their FDA trials.
More consulting agreements (OWCP currently has 3 consulting agreements).
Phase 1 FDA for sublingual tablet to treat PTSD.
Phase 1 FDA for sublingual tablet to treat Migraines.
Phase 1 FDA for sublingual tablet to treat multiple myeloma.
(1)
(0)
